Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCW9218 in Advanced Solid Tumors
NCT05322408Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2022
- Primary completion
- Jan 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HCW9218 in solid tumor, sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Apr 2022; status: completed.
02
Drugs
HCW9218
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05322408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322408.